Frankfurt

• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-521950-41-00 5 severe uncontrolled asthma
• A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indicat … Pending
  2025-522362-78-00 6 severely active ulcerative colitis (US) and CD (Crohn’s disease)
• A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o … Pending
  2025-523117-28-00 4 Relapsed or Refractory Multiple Myeloma
• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 4 2026-05-20 Idiopathic Pulmonary Fibrosis (IPF)
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU … Recruiting
  2023-506414-46-00 5 2022-04-22 High risk patients defined as having at least one of the following ris
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an … Recruiting
  2024-519976-19-00 5 2025-11-26 Asthma with type 2 inflammation characterized by an eosinophilic pheno
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients with Coronavirus Disease 2019 (COVID-19) who ar … Recruiting
  2024-517727-39-00 5 2025-07-28 Covid-19 at high risk of progression to severe illness.
• Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting
  2024-513959-33-00 4 2025-05-13 Asthma
• A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph … Recruiting
  2024-515162-13-00 5 2025-04-29 Eosinophilic Asthma
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• TOASST Study: Taper Or Abrupt Steroid STop? Recruiting
  2024-517334-18-00 6 2022-04-06 Inflammatory or autoimmune disorders
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended recruitment
  2022-502878-16-00 5 2025-01-23 Acute ischemic strokes with incomplete reperfusion
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis

Showing 1–24 of 44 trials